ArticleCancers2025

Baseline Radiomics as a Prognostic Tool for Clinical Benefit from Immune Checkpoint Inhibition in Inoperable NSCLC Without Activating Mutations.

Fedor Moiseenko et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.